PTO/SB/26 (04-07)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING
REJECTION OVER A "PRIOR" DATENT

REJECTION OVER A "PRIOR" DATENT

ODDOCKHOMMENT OF THE PRIOR OF THE PRIO

In te Application of: CHIEN-ROOM RAN ET AL.
Application No.: 10/787,417
Filed: February 27, 2004
For: COMBINATION IMMEDIATE RELEASE CONTROLLED RELEASE LEVODOPA/CARBIDOPA DOSAGE FORMS
The owner", IMPAX LABCRATORIES, INC. of
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 30 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure to pay a maintenance fee; is held unenforceable; is the dunenforceable; is tought in the prior of competent fursidistion; is tought invalid by a court of competent fursidistion;
is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is relissued: or
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.
Check either box 1 or 2 below, if appropriate.
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the file so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may lepondruce the validity of the application or any patient issued thereon.
The undersigned is an attorney or agent of record. Reg. No. 30,368
Y 57
September 28, 2007
Signature Date
Kendrew H. Colton
Typed or printed name
(202) 419-7000
Telephone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.
WARNING: Information on this form may become public. Credit card information should not
be Included on this form. Provide credit card information and authorization on PTO-2038.
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.
This collection of information is required by 37 CFR 1321. The information is required to obtain or retain a benefit by the public which is 16 to 16 (and by the USPTO process) an application. Conditionality is governed by 35 U.S. C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including atthering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comment on the amount of the you require to complete this form and/or suggestions for rectaining this burden, should be sent to the Chefri Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, P.C. Box 1450, Alexandria, V.A. 2231-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. 804 1450, Alexandria, V.A. 2231-1450,